IDH1 and central nervous system cancer: IDH1‐mutant gliomas are typically less aggressive and more responsive to therapy than wild‐type gliomas, resulting in improved prognosis for patients [8, 9, 10]; meanwhile, wild‐type gliomas have a median overall survival time of only 12 months, with less than 5% of patients surviving to 5 years [11].